REGISTER HERE.

This year’s virtual symposium provides a comprehensive update on the prevention, diagnosis and management of heart failure (HF). The program includes lectures presented by experts in the field. The extensive list of topics includes latest information on the management of hyperlipidemia, prevention of HF in patients with diabetes, extensive review of new drugs for the management of chronic HF and pulmonary hypertension, management of electrolyte abnormalities in HF, remote hemodynamic monitoring for prevention of hospitalizations, diagnosis, management of HF with reduced and preserved ejection fraction and the approach to patients with new classification of mid range ejection fraction. The program also includes discussion of new biomarkers, rate versus rhythm control and prevention of stroke in-patients with HF and atrial fibrillation, innovations in electrophysiological device, amyloidosis, percutaneous interventions and surgical revascularization and the value of myocardial viability assessment inpatients with ischemic cardiomyopathy, and transcatheter mitral valve repair for functional mitral regurgitation and COVID-19 and HF. The 2021 program has been designed to provide a high level and clinically relevant update with a goal of improving the care of patients with heart failure.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, the participants should be able to:

1. Review recent guidelines for the management of HF.
2. Manage volume overload in hospitalized patients with HF and review new recommendations for the use of diuretics.
3. Learn how to use SGLT2 inhibitors in the treatment of HF.
4. Review the effects and role of the new drugs vericiguat and Omecamptiv in the management of HF.
5. Provide an update on the diagnosis and management of various cardiomyopathies.
6. Review new technologies for the management of mitral and tricuspid regurgitation.
7. Understand the role of genetic testing in patients with cardiomyopathies.
8. Review the definition, outcome and management of patients with recovered ejection fraction.
9. Review the innovations in the area of ventricular assist devices in the management of advanced HF.
10. Review innovations in the use of new devices for the treatment of acute decompensated heart failure.
11. Discuss the use of biomarkers for the diagnosis and management of heart failure.
12. Discuss the approach for the diagnosis and management of heart failure with preserved ejection fraction.
13. Discuss the role of artificial intelligence to diagnose and manage heart failure.
14. Discuss the hemodynamic and clinical effect of inter atrial shunt in the treatment of heart failure.
15. Review the recent real- world experience with remote hemodynamic monitoring for the prevention of hospitalizations.

TARGET AUDIENCE

This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.

ACCREDITATION

The AAFP has reviewed 25th Annual Heart Failure 2021: An Update on Therapy and deemed it acceptable for up to 8.25 Online Only, Live AAFP Prescribed credit. Term of Approval is from 03/12/2021 to 03/13/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA / AAFP Equivalency:
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

For more information please visit the official event page.